CN101801391B - 透明质酸在制备用于改善皮肤、眼和粘膜的保护功能的组合物中的用途 - Google Patents

透明质酸在制备用于改善皮肤、眼和粘膜的保护功能的组合物中的用途 Download PDF

Info

Publication number
CN101801391B
CN101801391B CN2008801063138A CN200880106313A CN101801391B CN 101801391 B CN101801391 B CN 101801391B CN 2008801063138 A CN2008801063138 A CN 2008801063138A CN 200880106313 A CN200880106313 A CN 200880106313A CN 101801391 B CN101801391 B CN 101801391B
Authority
CN
China
Prior art keywords
days
purposes
hyaluronic acid
skin
molecular weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2008801063138A
Other languages
English (en)
Chinese (zh)
Other versions
CN101801391A (zh
Inventor
A·布里辛
E·皮谢勒
J-M·赞姆
M·米利奥
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Santé et de la Recherche Médicale
Agro Industrie Recherches et Developpements ARD
Original Assignee
Institut National de la Santé et de la Recherche Médicale
Agro Industrie Recherches et Developpements ARD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National de la Santé et de la Recherche Médicale, Agro Industrie Recherches et Developpements ARD filed Critical Institut National de la Santé et de la Recherche Médicale
Publication of CN101801391A publication Critical patent/CN101801391A/zh
Application granted granted Critical
Publication of CN101801391B publication Critical patent/CN101801391B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/671—Vitamin A; Derivatives thereof, e.g. ester of vitamin A acid, ester of retinol, retinol, retinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/676—Ascorbic acid, i.e. vitamin C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/678—Tocopherol, i.e. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Otolaryngology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Cosmetics (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
CN2008801063138A 2007-07-23 2008-07-04 透明质酸在制备用于改善皮肤、眼和粘膜的保护功能的组合物中的用途 Expired - Fee Related CN101801391B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0705349 2007-07-23
FR0705349A FR2919185B1 (fr) 2007-07-23 2007-07-23 Utilisation d'acide hyaluronique pour la preparation de compositions destinees a l'amelioration notamment de l'etat des muqueuses
PCT/FR2008/000959 WO2009024677A2 (fr) 2007-07-23 2008-07-04 Utilisation d'acide hyaluronique pour la preparation de compositions destinees a l'amelioration notamment de la fonction de protection de la peau, de l'oeil et des muqueuses

Publications (2)

Publication Number Publication Date
CN101801391A CN101801391A (zh) 2010-08-11
CN101801391B true CN101801391B (zh) 2013-07-10

Family

ID=39088885

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2008801063138A Expired - Fee Related CN101801391B (zh) 2007-07-23 2008-07-04 透明质酸在制备用于改善皮肤、眼和粘膜的保护功能的组合物中的用途

Country Status (9)

Country Link
US (1) US8895532B2 (cg-RX-API-DMAC7.html)
EP (1) EP2167102B1 (cg-RX-API-DMAC7.html)
JP (1) JP2010534225A (cg-RX-API-DMAC7.html)
KR (1) KR20100059786A (cg-RX-API-DMAC7.html)
CN (1) CN101801391B (cg-RX-API-DMAC7.html)
BR (1) BRPI0814446A2 (cg-RX-API-DMAC7.html)
ES (1) ES2588190T3 (cg-RX-API-DMAC7.html)
FR (1) FR2919185B1 (cg-RX-API-DMAC7.html)
WO (1) WO2009024677A2 (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010003797A1 (en) * 2008-07-09 2010-01-14 Novozymes Biopharma Dk A/S Hyaluronic acid for corneal wound healing
FR2963240B1 (fr) * 2010-07-28 2013-03-15 Horus Pharma Composition a usage topique sans conservateur comprenant de l'acide hyaluronique
RU2624239C2 (ru) 2011-06-03 2017-07-03 Аллерган, Инк. Составы кожного наполнителя, включая антиоксиданты
US20130096081A1 (en) 2011-06-03 2013-04-18 Allergan, Inc. Dermal filler compositions
US9408797B2 (en) 2011-06-03 2016-08-09 Allergan, Inc. Dermal filler compositions for fine line treatment
US9393263B2 (en) 2011-06-03 2016-07-19 Allergan, Inc. Dermal filler compositions including antioxidants
HUE037474T2 (hu) * 2011-07-07 2018-08-28 Holy Stone Healthcare Co Ltd Készítmény gyulladással kapcsolatban rendellenesség kezelésében és megelõzésében történõ alkalmazásra
TWI466675B (zh) 2011-09-16 2015-01-01 Univ China Medical 用於抑制發炎之醫藥組合物
CN102669681A (zh) * 2012-06-09 2012-09-19 东莞市照燕生物科技有限公司 一种保护胃肠粘膜的营养保健品
WO2014063735A1 (en) 2012-10-25 2014-05-01 Mdt Int'l S.A. Mucoadhesive compositions comprising hyaluronic acid and chitosan for topical application
JP2015063510A (ja) * 2013-06-28 2015-04-09 キユーピー株式会社 肌の保湿機能向上に関わる保湿関連遺伝子発現促進剤
EP3328353B1 (en) 2015-07-27 2024-04-10 Mary Kay, Inc. Topical skin formulations
JP6718728B2 (ja) * 2016-04-06 2020-07-08 キユーピー株式会社 アンチポリューション剤およびアンチポリューション用皮膚外用組成物
US20210000910A1 (en) 2019-07-03 2021-01-07 Jysk Skin Solutions Pte Ltd Topical compositions
WO2022236585A1 (zh) * 2021-05-10 2022-11-17 傅毓秀 玻尿酸用于制备治疗肺纤维化药剂的用途
TWI816119B (zh) * 2021-05-10 2023-09-21 國立陽明交通大學 玻尿酸用於製備治療急性呼吸窘迫症藥劑之用途
WO2022236599A1 (zh) * 2021-05-10 2022-11-17 傅毓秀 玻尿酸用于制备治疗急性呼吸窘迫症药剂的用途
CN115317504A (zh) * 2021-05-10 2022-11-11 傅毓秀 玻尿酸用于制备治疗急性呼吸窘迫症药剂的用途
EP4426317A1 (en) * 2021-11-05 2024-09-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of low molecular weight hyaluronic acid for the treatment of lung mucosal inflammation
US12083204B2 (en) 2022-06-02 2024-09-10 L'oreal Topical composition for homeostatic delivery of nitric oxide and uses thereof
WO2024194437A1 (en) * 2023-03-22 2024-09-26 Institut National de la Santé et de la Recherche Médicale Use of low molecular weight hyaluronic acid for promoting ciliated cell differentiation

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166331A (en) * 1983-10-10 1992-11-24 Fidia, S.P.A. Hyaluronics acid fractions, methods for the preparation thereof, and pharmaceutical compositions containing same
WO2000001394A1 (en) * 1998-07-06 2000-01-13 Fidia Advanced Biopolymers S.R.L. Biocompatible and biodegradable compositions containing hyaluronic acid and the derivatives thereof for the treatment of ulcers in the digestive apparatus
WO2002069984A2 (de) * 2001-03-02 2002-09-12 Hans-Knöll-Institut für Naturstoff-Forschung e.V. Verwendung von hyaluronsäure-uroniden zur behandlung von entzündlichen vorgängen
WO2003049747A1 (de) * 2001-12-12 2003-06-19 Ursapharm Arzneimittel Gmbh & Co. Kg Pharmazeutische zusammensetzung zur ophtalmologischen und rhinologischen anwendung
WO2006072243A1 (en) * 2005-01-03 2006-07-13 Novozymes Biopolymer A/S Hyaluronic acid fraction with moisturizing and anti-wrinkle properties

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4303676A (en) * 1980-03-21 1981-12-01 Balazs Endre A Hyaluronate based compositions and cosmetic formulations containing same
US4517295A (en) * 1983-02-18 1985-05-14 Diagnostic, Inc. Hyaluronic acid from bacterial culture
JPS59219209A (ja) * 1983-05-28 1984-12-10 Kanebo Ltd 皮膚化粧料
IT1260148B (it) * 1992-04-17 1996-03-28 Fidia Spa Impiego di preparazioni di acido ialuronico per la formazione di tessuto osseo
DE10161149B4 (de) * 2001-12-12 2007-03-08 Ursapharm Arzneimittel Gmbh & Co. Kg Verwendung von Heparin-haltigem Ophthalmikum
US7241456B2 (en) * 2002-10-25 2007-07-10 Australian Importers Ltd. Formulations for topical delivery of bioactive substances and methods for their use
FR2847818B1 (fr) * 2002-11-28 2008-04-04 Agro Ind Rech S Et Dev Ard Composition pharmaceutique a base d'acide hyaluronique
JP4576583B2 (ja) * 2005-03-22 2010-11-10 キユーピー株式会社 ヒアルロン酸またはその塩、およびその製造方法、ならびにこれを含有する化粧料および食品組成物

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166331A (en) * 1983-10-10 1992-11-24 Fidia, S.P.A. Hyaluronics acid fractions, methods for the preparation thereof, and pharmaceutical compositions containing same
WO2000001394A1 (en) * 1998-07-06 2000-01-13 Fidia Advanced Biopolymers S.R.L. Biocompatible and biodegradable compositions containing hyaluronic acid and the derivatives thereof for the treatment of ulcers in the digestive apparatus
WO2002069984A2 (de) * 2001-03-02 2002-09-12 Hans-Knöll-Institut für Naturstoff-Forschung e.V. Verwendung von hyaluronsäure-uroniden zur behandlung von entzündlichen vorgängen
WO2003049747A1 (de) * 2001-12-12 2003-06-19 Ursapharm Arzneimittel Gmbh & Co. Kg Pharmazeutische zusammensetzung zur ophtalmologischen und rhinologischen anwendung
WO2006072243A1 (en) * 2005-01-03 2006-07-13 Novozymes Biopolymer A/S Hyaluronic acid fraction with moisturizing and anti-wrinkle properties

Also Published As

Publication number Publication date
US8895532B2 (en) 2014-11-25
CN101801391A (zh) 2010-08-11
HK1145149A1 (en) 2011-04-08
WO2009024677A3 (fr) 2009-12-03
JP2010534225A (ja) 2010-11-04
BRPI0814446A2 (pt) 2015-01-06
FR2919185B1 (fr) 2010-09-10
ES2588190T3 (es) 2016-10-31
EP2167102B1 (fr) 2016-05-25
KR20100059786A (ko) 2010-06-04
EP2167102A2 (fr) 2010-03-31
US20100210585A1 (en) 2010-08-19
FR2919185A1 (fr) 2009-01-30
WO2009024677A2 (fr) 2009-02-26

Similar Documents

Publication Publication Date Title
US8895532B2 (en) Use of hyaluronic acid for the preparation of compositions intended for improving in particular the protective function of the skin, the eye and the mucous membranes
Chegini et al. The destruction of mucosal barriers, epithelial remodeling, and impaired mucociliary clearance: possible pathogenic mechanisms of Pseudomonas aeruginosa and Staphylococcus aureus in chronic rhinosinusitis
López-Boado et al. Macrolides as immunomodulatory medications for the therapy of chronic lung diseases
BR112014025469B1 (pt) Usos de lisado filtrado da bactéria probiótica lactobacillus rhamnosus gg atcc 53103 no reparo ou regeneração da barreira cutânea e no tratamento cosmético para aumentar a função de barreira cutânea
TWI913236B (zh) 新多功能寡肽
CN103945846A (zh) 包含瑞巴派特和泪液保持剂的用于治疗眼前段疾病的药物
KR20190011750A (ko) 엘라스타제 억제 활성을 갖는 베타-헤어핀 펩티드 모방체 및 이의 에어로졸 투여 형태
KR20190064745A (ko) 간엽줄기세포 유래 인공나노좀을 포함하는 폐질환 예방 또는 치료용 약학적 조성물
Wigenstam et al. Acute respiratory changes and pulmonary inflammation involving a pathway of TGF-β1 induction in a rat model of chlorine-induced lung injury
HK1145149B (en) Use of hyaluronic acid for preparing compositions for improving the function of skin, eye and mucous membrane protection
CN110870862A (zh) 岩白菜素在制备治疗体内肺炎克雷伯氏菌感染药物中的用途
US20240252581A1 (en) Compositions and methods for treating respiratory distress
US20210386668A1 (en) Cyclodextrin for use in the treatment and prevention of late phase bronchoconstriction in allergen-induced asthma
KR20130055580A (ko) 기도의 염증 및 이상성 점액섬모 전달의 치료법으로서의 에어로졸화 댑손
AU2020296829B2 (en) Method for treating asthma
KR102872873B1 (ko) 바이러스 감염증 치료용 약학 조성물 및 치료 방법
CN118236413B (zh) 一种能中和细菌毒素的蒲公英提取物及其应用
Qiu et al. Nrf2 Improves Airway Goblet Cell Metaplasia in Chronic Obstructive Pulmonary Disease (COPD) and Its Mechanism
BR112019027257A2 (pt) método para reduzir inflamação de pulmão
EP4051300A1 (en) Composition for the prevention and treatment of diseases of the respiratory system
CN114903973A (zh) 一种呼吸道粘膜免疫增强药物组合物
JP2025061025A (ja) 喘息、喘息悪化、アレルギー性喘息及び/又は関連疾患状態を呼吸器疾患に関連する微生物叢で治療及び/又は予防する方法
Shah et al. Biomimetic pulmonary drug delivery systems for COVID-19 management: current status, challenges, and future perspectives
US10035821B2 (en) Calcium binding compounds based on gamma-carboxy glutamate
CN122056905A (zh) 银锻苷在制备预防和治疗肺纤维化药物中的应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1145149

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1145149

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20130710

Termination date: 20160704